A Phase II Study of Alemtuzumab in Autoimmune Cytopenias
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To investigate the efficacy of alemtuzumab in terms of objective response rate (ORR: complete remission [CR], partial remission [PR]), progression free survival (PFS), and relapse rate in patients with autoimmune cytopenias
Wichean Mongkonsritragoon, M.D.
Phramongkutklao College of Medicine and Hospital
Thailand: Food and Drug Administration